Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf). 2011;33:496 502. S4.5-32. US Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: National Academies Press. 2010. Available at: http://www.ncbi. nlm.nih.gov/books/NBK219565. Accessed January 5, 2019. S4.5-33. US Department of Health and Human Services. The health conse- quences of smoking 50 years of progress: A report of the Surgeon General. ed. Atlanta, GA: 2014. S4.5-34. Tobacco Control Legal Consortium, Public Health Law Center. HUD s rule to restrict smoking in public housing: an overview. Available at: https://publichealthlawcenter.org/sites/default/files/resources/HUD- January 5, 2019. 4.6. Aspirin Use S4.6-1. Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the pri- mary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2016;164:804 13. S4.6-2. Whitlock EP, Burda BU, Williams SB, et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2016;164:826 35. S4.6-3. Lotrionte M, Biasucci LM, Peruzzi M, et al. Which aspirin dose and preparation is best for the long-term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta-analysis. Prog Cardiovasc Dis. 2016;58:495 504. S4.6-4. Raju N, Sobieraj-Teague M, Bosch J, et al. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med. 2016;129:e35 6. S4.6-5. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134 41. S4.6-6. Belch J, MacCuish A, Campbell I, et al. 